(URRE) Announces 1-for-12 Reverse Stock Split

CENTENNIAL, Colo., March 08, 2016  — Uranium Resources, Inc. (Nasdaq:URRE) (ASX:URI), a leading exploration, development, and uranium production company, announced today that the previously approved reverse split of its common stock became effective following the close of trading on March 7, 2016.  The consolidated common shares listed on Nasdaq and the CHESS Depository Interests (CDIs) listed on ASX are to begin trading on a split-adjusted basis as of March 8, 2016 and March 9, 2016, respectively.  On February 11, 2016 at a special meeting of stockholders, the Company received overwhelming support, with 93.2% voting “FOR” a charter amendment permitting the Company to affect a reverse split.  The primary purpose of the reverse split was to bring URI into compliance with Nasdaq’s $1.00 minimum bid price requirement to maintain the Company’s stock listing on Nasdaq.

When the reverse stock split becomes effective, every 12 shares of issued and outstanding URI common stock will be combined into one issued and outstanding share of common stock with no changes to the par value of the shares.  The reverse split will reduce the number of URI’s outstanding common stock from approximately 61.82 million shares to approximately 5.15 million shares.  In addition, effective upon the reverse stock split, the number of authorized shares of the Company’s common stock will be reduced from 200 million to 100 million.  The reverse split will also reduce the number of URI’s quoted CDIs on the ASX from approximately 10.3 million to approximately 861,000.  No fractional shares will be issued as a result of the reverse stock split.  Any fractional shares that would have resulted will be settled in cash.  In addition, the Company’s outstanding options will be consolidated in the same ratio as the common stock and the exercise price amended in inverse proportion to that ratio.

About Uranium Resources

Uranium Resources, Inc. (URI) is focused on advancing to near-term production the Temrezli in-situ recovery (ISR) project in Central Turkey. URI also controls extensive exploration properties under nine exploration and operating licenses covering approximately 32,000 acres (over 13,000 ha) with numerous exploration targets, including the potential satellite Sefaatli Project, which is 30 miles (48 km) southwest of the Temrezli Project. In Texas, the Company has two licensed and currently idled processing facilities and approximately 14,000 acres (5,700 ha) of prospective ISR projects. In New Mexico, the Company controls minerals rights encompassing approximately 190,000 acres (76,900 ha) in the prolific Grants Mineral Belt, which is one of the largest concentrations of sandstone-hosted uranium deposits in the world. Incorporated in 1977, URI also owns an extensive uranium information database of historic drill hole logs, assay certificates, maps and technical reports for the Western United States.

Uranium Resources Contact:
Robert Winters, Alpha IR Group
929-266-6315
www.uraniumresources.com

(ZYNE) to Present at 28th Annual ROTH Conference

DEVON, Pa., March 07, 2016  — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will present at the 28^th Annual ROTH Conference. The conference will be held March 13 to 16, at The Ritz Carlton Hotel in Dana Point, CA. Zynerba Chairman and CEO Armando Anido will present on Monday, March 14, at 11:00 am Eastern time.

To listen to a webcast of this presentation during the event, please visit the Investor Relations page of www.zynerba.com. A replay of this webcast will be available for 90 days following the conference.

About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a specialty pharmaceutical company focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Zynerba is developing therapeutic candidates based on proprietary transdermal technologies that, if successfully developed, may allow sustained, consistent and controlled delivery of therapeutic levels of two cannabinoids: cannabidiol (CBD), a non-psychoactive cannabinoid, and THC. Transdermal delivery has the potential to reduce adverse effects associated with oral dosing. ZYN002, the Company’s CBD Gel, is the first and only synthetic CBD formulated as a patent protected permeation-enhanced gel and is being studied in refractory epilepsy, Fragile X syndrome and osteoarthritis. Zynerba is also developing ZYN001, which utilizes a synthetically manufactured pro-drug of THC in a transdermal patch to deliver THC through the skin and into the bloodstream. ZYN001 will be studied in fibromyalgia and peripheral neuropathic pain. Learn more at www.zynerba.com and follow the Company on Twitter at @ZynerbaPharma.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. For example, there can be no guarantee that the Company will obtain approval for ZYN002 or ZYN001 from the U.S. Food and Drug Administration (“FDA”) or foreign regulatory authorities; even if ZYN002 or ZYN001 are approved, the Company may not be able to obtain the label claims that it is seeking from the FDA. Management’s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the success, cost and timing of the Company’s product development activities, studies and clinical trials; the success of competing products that are or become available; the Company’s ability to commercialize its product candidates; the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates; and the Company’s expectations regarding its ability to obtain and adequately maintain sufficient intellectual property protection for its product candidates. These and other risks are described under the heading “Risk Factors” in the registration statement on Form S-1 (commission file number 333-205355), which was declared effective by the Securities and Exchange Commission on August 4, 2015. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Investor Contacts
Richard Baron, CFO
Zynerba Pharmaceuticals
484.581.7505

Angeli Kolhatkar
Argot Partners
212.600.1902
angeli@argotpartners.com

Media Contact
Eliza Schleifstein
Argot Partners
973.361.1546
eliza@argotpartners.com

(NVIV) Significant Improvement of Fifth Neuro-Spinal Scaffold™ Patient

InVivo Therapeutics Holdings Corp. (NVIV) today announced a six-month post-implant update for the fifth patient in The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury.

All patients enrolled in The INSPIRE Study have complete (AIS A) injuries at the time of enrollment. In the time between the three-month and the six-month post-injury assessment, the fifth patient treated improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. The ASIA Impairment Scale (AIS) is a five grade scale (AIS A-E) that measures the severity of a spinal cord injury.

The primary endpoint of The INSPIRE Study is the proportion of patients with an improvement in AIS grade by the six-month visit. So far, three out of the first five patients treated (60%) have had an AIS grade improvement by 6 months. Several large natural history databases indicate that fewer than 16% of patients with complete thoracic injuries have an AIS grade improvement by six months post injury.*

As previously announced, the Objective Performance Criterion (OPC) measure of study success for The INSPIRE Study is defined as 25% or more of the patients improving by at least one AIS grade by six months post-implantation.

Mark Perrin, Chief Executive Officer and Chairman, said, “We are encouraged to see this patient’s significant neurological progress. This third conversion brings us one step closer to achieving the Objective Performance Criterion (OPC) for The INSPIRE Study. Our goal is to approach full enrollment of the pivotal INSPIRE study by the end of the year, which will allow for an HDE (Humanitarian Device Exemption) submission in 2017.”

About The INSPIRE Study

The INSPIRE Study is designed to demonstrate the safety and probable benefit of the Neuro-Spinal Scaffold™ for the treatment of complete T2-T12/L1 spinal cord injury in support of a Humanitarian Device Exemption (HDE) application for approval. The study is expected to enroll 20 patients. For more information, refer to https://clinicaltrials.gov/ct2/show/study/NCT02138110.

About the Neuro-Spinal Scaffold™ Implant

Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in The INSPIRE Study.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect,” “designed to,” “potentially,” and similar expressions, and include statements regarding the safety and effectiveness of the Neuro-Spinal Scaffold, progress toward achievement of OPC for The INSPIRE Study, the expected timing of full enrollment in the study, and the timing of the submission for Humanitarian Device Exemption (HDE). Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the company’s ability to commercialize its products; the company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2015, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

* Zariffa et al., Spinal Cord (2011); Lee et al., J. Spinal Cord Med. (2014); Fawcett et al., Spinal Cord (2007)

(EGLE) Analyst Coverage Initiated; What’s Causing This Rally

NEW YORK, NY / March 7, 2016 / Eagle Bulk Shipping Inc. (NASDAQ: EGLE), a company engaged in the ocean transportation of dry bulk cargoes worldwide, recently announced that it had filed an 8-K on Monday updating on the current agreement that it had in place and was previously announced in January. Pursuant to the 8-K, the company entered into Amendment No. 5 to Forbearance and Standstill Agreement. EGLE extend the Forbearance Period to allow the Company with additional time while discussions regarding financing alternatives are continuing. The news coupled with the massive rally in Iron, which appreciated 19% on Monday, on speculation of Chinese Stimulus, sent the stock of EGLE flying to over 140% by mid-day Monday.

The rally in iron, and other commodities, is said to be the result of speculation and short covering. Is the same true for EGLE or is the rally in the stock sustainable?

For a more detailed research report with analyst comments on Eagle Bulk Shipping Inc. (NASDAQ: EGLE) please follow the link. There is no cost obligation required to view analyst brief: http://broadstreetalerts.com/egle-analyst/.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the subject company in this report to be materially different from the statements made herein.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. Information in this release is fact checked and produced on a best efforts basis by Robert Borowski. An outsourced research services provider represented by Robert Borowski, provided Broad Street Alerts this article or report. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. Broad Street Alerts is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Robert Borowski. The subject Company has not compensated Broad Street Alerts or Robert Borowski for the creation or dissemination of this report. Broad Street Alerts is the party responsible for issuing the press release and for hosting the full analyst report on Broad Street Alerts website. Robert Borowski is the author of research report. This information is submitted to increase awareness for the Broad Street Alerts brand to our subscriber base and the investing public.

If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at admin@broadstreetalerts.com. For any urgent concerns or inquiries, please contact us at admin@broadstreetalerts.com.

NOT FINANCIAL ADVICE

Broad Street Alerts makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Broad Street Alerts is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming Broad Street Alerts has compensated Robert Borowski, up to two hundred fifty dollars for the distribution rights to disseminate analyst report. No liability is accepted by Broad Street Alerts whatsoever for any direct, indirect or consequential loss arising from the use of this document. Broad Street Alerts expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Broad Street Alerts does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

(CLRB) to Host Conference Call on March 10

MADISON, Wis., March 07, 2016  — Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, today announces that management will host a teleconference and live webcast to report year end 2015 financial results, followed by a review of corporate performance and 2016 objectives, on March 10 at 5:00 PM EST.

Event Details

Interested investors may participate in the conference call by dialing (888) 646-8293 (US domestic) or (973) 453-3065 (international) or participate via webcast. The live and archived webcast can be accessed via the company’s website at http://investor.cellectarbiosciences.com/events.cfm.

About Cellectar Biosciences, Inc.

Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar’s PDC Delivery Platform is based on the company’s proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar’s PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The Company’s lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase 1 study in patients with relapsed or refractory multiple myeloma. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For additional information please visit www.cellectarbiosciences.com.

This news release contains forward-looking statements. You can identify these statements by our use of words such as “may,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” “continue,” “plans,” or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators’ ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended December 31, 2014. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

INVESTOR AND MEDIA CONTACT: 
Jules Abraham
JQA Partners
917-885-7378
jabraham@jqapartners.com

(ISCO) Announces Commencement of Enrollment of Phase I Trial of ISC-hpNSC

Melbourne Health Ethics Committee Approves Phase I Clinical Trial for Treatment of Parkinson’s Disease

(CNCK) Engages PCG Advisory Group as Investor and Public Relations Agency

(BLPH) to Present at the Cowen and Company 36th Annual Health Care Conference

WARREN, N.J., March 04, 2016  — Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it will present in the Cowen and Company 36^th Annual Health Care Conference. Jonathan Peacock, Bellerophon’s Chairman and Chief Executive Officer, will provide a company update at 2:00 pm ET on Monday, March 7, 2016.

About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery device. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company intends to commence Phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), which is in Phase 2 development and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF). The Company’s plans also call for the completion of further work on the use of INOpulse to treat PH-COPD and PH-IPF during 2016.  For more information, please visit www.bellerophon.com.

Contact
At Bellerophon:	
Amy Edmonds, Vice President	
Head of Clinical Operations &	
Administration	
(908) 574-4765

At Rx Communications Group:
Melody Carey
(917) 322-2571
mcarey@rxir.com

(MEMP) Announces Resignation of Directors

HOUSTON, March 04, 2016  — The Board of Directors (the Board) of Memorial Production Partners GP LLC, the general partner of Memorial Production Partners LP (NASDAQ:MEMP), announced today that Scott Gieselman, Kenneth Hersh and Tony Weber have resigned as directors effective immediately.  The resignations announced today are not related to any disagreement with MEMP’s operations, policies or practices.

The Board also announced the appointment of William J. (“Bill”) Scarff to serve as a director. There are currently no plans to fill the remaining vacated seats on the Board.

In connection with this announcement, Tony Weber commented, “NGP has played an integral role in MEMP’s development and success and was the guiding force behind MEMP’s initial public offering in 2011.  We are pleased with the progress made at MEMP since its initial public offering and believe the Partnership has positioned itself strategically to withstand the current market environment.  NGP continues to value MEMP’s strong management team and remains confident in its ability to manage the Partnership going forward.  The resignations reflect the limited duration of private equity backed investments and is a natural occurrence in the life of a private equity firm.”

John Weinzierl, Chairman and CEO stated, “On behalf of the Board and the Partnership, I want to thank Messrs. Gieselman, Hersh and Weber for their years of service to MEMP. They have been invaluable resources to the Board, and the Partnership has benefited greatly from their professionalism, dedication and experience. NGP has provided strong support and valued input to the Partnership, and we are extremely proud of what we’ve accomplished together.”  Mr. Weinzierl continued by stating, “We are pleased with the addition of Bill Scarff to the Board.  He brings to the Board over 30 years of oil and gas industry experience, including starting and leading successful private energy companies, and has made significant contributions to the Partnership since he became President in January 2014.  Bill’s extensive background and familiarity with the Partnership will be of great benefit to the Board.”

About Memorial Production Partners LP

Memorial Production Partners LP is a publicly traded partnership engaged in the acquisition, production and development of oil and natural gas properties in the United States.  MEMP’s properties consist of mature, legacy oil and natural gas fields.  MEMP is headquartered in Houston, Texas.  For more information, visit www.memorialpp.com.

Forward-Looking Statements

This press release includes “forward-looking statements.” All statements, other than statements of historical facts, included in this press release that address activities, events or developments that MEMP expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements include, but are not limited to, statements about MEMP’s future capital expenditures (including the amount and nature thereof), expectations regarding cash flows, distributions and distribution rates, and expectations of plans, goals, strategies (including measures to implement strategies), objectives and anticipated financial and operating results of MEMP, including as to production, lease operating expenses, hedging activities, commodity price realizations, capital expenditure levels and other guidance included in this presentation.  Terminology such as “will,” “may,” “should,” “expect,” “anticipate,” “plan,” “project,” “intend,” “estimate,” “believe,” “target,” “continue,” “potential,” the negative of such terms or other comparable terminology often identify forward-looking statements.  These statements are based on certain assumptions made by MEMP based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of MEMP, which may cause MEMP’s actual results to differ materially from those implied or expressed by the forward-looking statements. These include, but are not limited to, the following risks and uncertainties: the uncertainty inherent in the development and production of oil and natural gas and in estimating reserves; risks associated with drilling activities; potential difficulties in the marketing of, and volatility in the prices for, oil, natural gas and natural gas liquids; competition in the oil and natural gas industry; potential failure or shortages of, or increased costs for, drilling and production equipment and supply materials for production; risks related to acquisitions, including MEMP’s ability to integrate acquired properties; risks related to MEMP’s ability to generate sufficient cash flow to pay distributions, to make payments on its debt obligations and to execute its business plan; MEMP’s ability to access funds on acceptable terms, if at all, because of the terms and conditions governing MEMP’s indebtedness or otherwise; and the risk that MEMP’s hedging strategy may be ineffective or may reduce its income.  Please read MEMP’s filings with the SEC, which are available on MEMP’s Investor Relations website at http://investor.memorialpp.com/sec.cfm or on the SEC’s website at http://www.sec.gov, for a discussion of certain risks and uncertainties that could cause actual results to differ from those in such forward-looking statements.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by these cautionary statements.  MEMP has no intention, and disclaims any obligation, to update or revise any forward-looking statements, whether as a result of new information, future results or otherwise.

Contact
Memorial Production Partners LP
Ronnetta Eaton - Manager, Investor Relations
(713) 588-8350                                              
ir@memorialpp.com

(REXX) Announces Extension of Offer

STATE COLLEGE, Pa., March 04, 2016  — Rex Energy Corporation (the “Company”) (Nasdaq:REXX) announced today that it has extended its previously announced exchange offer and consent solicitation related to the Company’s outstanding 8.875% Senior Notes due 2020 (the “2020 Notes”) and 6.250% Senior Notes due 2022 (the “2022 Notes” and, together with the 2020 Notes, the “Existing Notes”). The Company is offering to exchange (the “Exchange Offer”) any and all of the Existing Notes held by eligible holders for up to (i) $480,000,000 aggregate principal amount of the Company’s new 10.00% Senior Secured Second Lien Notes due 2020 (the “New Notes”) and (ii) 10,125,000 shares of the Company’s common stock (the “Shares”), upon the terms and subject to the conditions set forth in the Company’s Confidential Offering Memorandum and Consent Solicitation Statement (the “Offering Memorandum”) and related Letter of Transmittal, each dated February 3, 2016. Concurrently with the Exchange Offer, the Company is soliciting consents (the “Consent Solicitation”) from eligible holders to proposed amendments to the indentures governing the Existing Notes that would eliminate certain restrictive covenants. As a result of the extension, the Exchange Offer and Consent Solicitation is now set to expire at 9:00 a.m., New York City time, on March 22, 2016 (the “Extended Expiration Time”), unless further extended. The Exchange Offer and Consent Solicitation was originally set to expire at 9:00 a.m., New York City time, on March 3, 2016 (the “Original Expiration Time”). Holders who validly tender Existing Notes prior to the Extended Expiration Time will be eligible to receive the applicable Total Exchange Consideration (as defined in the Offering Memorandum) (which includes the Early Tender Premium (as defined in the Offering Memorandum)).

Except as set forth herein, all of the other terms of the Exchange Offer and Consent Solicitation set forth in the Offering Memorandum remain unchanged.  As of this date, tenders of approximately $137,837,000 aggregate principal amount, or 39.38%, of the 2020 Notes and tenders of approximately $129,849,000 aggregate principal amount, or 39.95%, of the 2022 Notes have been received pursuant to the Exchange Offer.  Holders who have validly tendered Existing Notes prior to the Original Expiration Time may withdraw tenders of Existing Notes at any time prior to the Extended Expiration Time.

The New Notes and Shares to be offered have not been registered under the Securities Act or any state securities laws, and unless so registered, may not be offered or sold in the United States or to U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of any of these securities, in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Rex Energy Corporation

Headquartered in State College, Pennsylvania, Rex Energy is an independent oil and gas exploration and production company operating in the Appalachian and Illinois Basins within the United States. The company’s strategy is to pursue its higher potential exploration drilling prospects while acquiring oil and natural gas properties complementary to its portfolio.

Forward-Looking Statements

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Forward-looking statements are based on current beliefs and expectations and involve certain assumptions or estimates that involve various risks and uncertainties, such as financial market conditions, changes in commodities prices and the other risks discussed in detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 and other subsequent filings with the Securities and Exchange Commission. Readers should not place undue reliance on any such forward-looking statements, which are made only as of the date hereof. Rex Energy has no duty, and assumes no obligation, to update forward-looking statements as a result of new information, future events or changes in the Company’s expectations.

Contact:

Investor Relations
(814) 278-7130
InvestorRelations@rexenergycorp.com

(ORIG) Announces Fourth Quarter 2015 Results Release Date

(QUMU) Extends the Value of Unified Communications Platforms

Qumu (NASDAQ: QUMU), the leader in enterprise video, today announced the availability of a certified extension to the Pexip Infinity meeting platform that simplifies the recording, management, distribution and replay of Pexip meetings to make these valuable content assets easily searchable and accessible to an organization. The Pexip add-on is the first of many planned integrations with UC solutions to be powered by the innovative Qumu UC Gateway.

Video is growing rapidly as an enterprise communication tool, greatly increasing the volume of video meetings. One Fortune 100 company recently reported conducting 40,000 video calls in a typical week. This higher volume of unified communications (UC) video is stressing legacy UC video platforms, while the increasing number of UC video solutions deployed within a single organization is fragmenting workflows, further limiting the ability of companies to record and share this valuable knowledge.

Qumu’s industry-leading UC Gateway capability, a feature of the Qumu video platform, enables Qumu to integrate with a company’s unified communications ecosystem – including video conferencing, web conferencing and scheduling applications – to make recording calls a seamless part of starting any meeting.

After the conference, the recordings are stored, distributed and managed centrally using enterprise-class content management capabilities such as security, search, and availability on all devices. The Qumu video platform can scale to archive millions of recordings from a company’s multiple video conference and web conference solutions, providing a long-term video content platform that will remain constant as UC technologies evolve over time.

“Enterprises today are challenged by a diverse UC video portfolio, including legacy hardware-based UC installations, legacy web conferencing applications and the newest software or cloud-based solutions,” said Vern Hanzlik, president and CEO of Qumu. “The Qumu platform gives organizations a way to capture and manage valuable knowledge assets from all of their UC platforms, both today and in the future.”

Qumu now available for Pexip Infinity solutions

The Qumu Pexip extension is now available as an option to integrate with Pexip Infinity. Enterprises running Pexip Infinity solutions can thus easily record, store and play back Pexip conferences. With the Qumu option, Pexip conferences may also be live streamed to add hundreds or thousands of one-way viewers to the meeting.

“The ability to record, store, play back, and stream meetings and conferences is an essential feature for many of our enterprise customers,” said Åsmund Fodstad, CEO of Pexip. “Seamlessly integrating with Qumu’s recognized and market leading enterprise video content management platform makes all that easy for them, with a flexible solution that scales and adapts to their requirements.”

“Working with a global video conferencing leader like Pexip is an honor for Qumu,” said Mr. Hanzlik. “We believe Pexip’s Infinity platform sets the standard for future UC and video infrastructure, and as a leader in enterprise video content management, we’re very excited to add value for Pexip’s customers through the addition of simple-to-use enterprise video content management capabilities.”

Ask your Pexip representative for more information on the Qumu certified extension as part of a Pexip solution.

Join the conversation about extending the value of virtual meetings with this interactive infographic.

About Qumu Corporation

Video is today’s document. Qumu (NASDAQ: QUMU) provides the tools businesses need to create, manage, secure, deliver and measure the success of their videos. Qumu’s innovative solutions release the power in video to engage and empower employees, partners and clients. Organizations around the world realize the greatest possible value from video they create and publish using Qumu. Whatever the audience size, viewer device or network configuration, Qumu solutions are how business does video. www.qumu.com

About Pexip

Since 2012, Pexip has worked towards enabling enterprises and organizations to provide every one of their users with video based communications and visual collaboration tools.

The company’s award-winning virtualized meeting platform enables seamless joining of video, audio, and web conferencing across incompatible technologies such as traditional videoconferencing and Microsoft’s Skype for Business. Whether running in an organization’s data center, in a public, private or hybrid cloud, Pexip Infinity provides unmatched capacity and capabilities. The company’s core product is used by several Fortune 500 organizations across a variety of industries. In addition, it powers a large number of the world’s Videoconferencing as a Service (VCaaS) providers. The company experienced more than 300% growth in 2015, and now simplifies communications in thousands of organizations.

Pexip employs more than 80 people on five continents, and has main offices in Oslo, Norway (HQ), London, and New York.

Learn more at www.pexip.com

(AUPH) Receives FDA Fast Track for Voclosporin in Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for voclosporin, the Company’s next generation calcineurin inhibitor, for the treatment of Lupus Nephritis (LN).

The Fast Track program was created by the FDA to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address significant unmet medical needs. Compounds that receive this FDA designation benefit from more frequent meetings and communications with the FDA to review the drug’s development plan including the design of clinical trials and the use of biomarkers to support approval. Additionally, Fast Track designation allows the Company to submit parts of the New Drug Application (NDA) on a rolling basis for review as data becomes available.

The Company’s 265 patient Phase 2b trial, called AURA (Aurinia Urine protein Reduction in Active Lupus with voclosporin) has recently completed enrollment and is currently underway in over 20 countries worldwide. It is a randomized, controlled, double-blind study comparing the efficacy of two doses of voclosporin plus mycophenolate mofetil (MMF) vs. MMF alone in patients with active LN. There will be a primary analysis to determine complete remission at week 24 and various secondary analyses at week 48 which include biomarkers and markers of non-renal SLE. The Company expects to analyse and review the AURA data with the FDA later in 2016 in order to reach agreement on further clinical development requirements.

“It is encouraging that Fast Track designation has been granted for voclosporin and we look forward to working closely with FDA as we complete the AURA trial. This designation demonstrates the substantial unmet medical need for patients with LN and potentially helps move a promising therapy through the FDA more rapidly.” said Lawrence Mandt, Aurinia’s Vice President of Regulatory Affairs & Quality.

About Aurinia

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. The fully-enrolled Phase 2b AURA-LV clinical trial is evaluating the efficacy of its lead drug, voclosporin, as a treatment for active LN. LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.

Voclosporin is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with extensive clinical data in over 2,000 patients in other indications. Voclosporin is made by a modification of a single amino acid of the cyclosporine molecule (a CNI approved for use in transplant patients since 1983). This modification results in a more predictable pharmacokinetic and pharmacodynamic relationship, an increase in potency vs. cyclosporine, an altered metabolic profile, and potential for flat dosing.

About AURA:

The AURA study or “Aurinia Urine Protein Reduction in Active Lupus Nephritis Study” is an adequate and well-controlled clinical trial that enrolled 265 patients and is being conducted in over 20 countries worldwide. This trial will compare the efficacy of voclosporin against placebo in achieving remission in patients with active lupus nephritis. The AURA study is designed to demonstrate that voclosporin can induce a rapid and sustained reduction of proteinuria in the presence of extremely low steroid exposure. It will compare two dosage groups of voclosporin (23.7mg and 39.5mg) compared to placebo, with all patients receiving mycophenolate mofetil (MMF) and oral corticosteroids as background therapy. There will be a primary analysis to determine complete remission at week 24 (confirmed at 26 weeks) and various secondary analyses at week 48 which include biomarkers and markers of non-renal SLE.

We seek Safe Harbor.

Aurinia Pharmaceuticals Inc.
Mr. Michael Martin, 250-708-4272
Chief Operating Officer
Fax: 250-744-2498
mmartin@auriniapharma.com
or
Renmark Financial Communications Inc.
Barry Mire, 416-644-2020
bmire@renmarkfinancial.com
or
Laura Welsh, 514-939-3989
lwelsh@renmarkfinancial.com

(ADXS) Study in Head and Neck Cancer Selected for AACR Annual Meeting

PRINCETON, N.J., March 02, 2016  — Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that data from a Phase 2 study of its lead Lm immunotherapy candidate in HPV-associated head and neck cancer, axalimogene filolisbac (AXAL), has been selected as a late-breaker poster presentation at the American Association for Cancer Research (AACR) Annual Meeting. According to AACR’s selection criteria, late-breaking abstracts demonstrate highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline. Additionally, only abstracts deemed to be of high scientific priority are accepted for presentation.

The Phase 2 study by Andrew G. Sikora, M.D., Associate Professor of Otolaryngology and co-director of the Head and Neck Cancer Program in the NCI Comprehensive-Designated Dan L. Duncan Cancer Center at Baylor College of Medicine, is evaluating the efficacy of axalimogene filolisbac as neoadjuvant treatment prior to robot-assisted surgery in patients with HPV-associated head and neck cancer. The poster will present data on the effect of axalimogene filolisbac in targeting and inducing a T-cell response in the tumor microenvironment. The study received a three-year $1.1 million grant from the U.S. Food and Drug Administration’s Office of Orphan Products Development, which funds research for the development of products for rare diseases.

“Our research into the potential of AXAL in targeting HPV-related cancers continues to make remarkable progress. We are pleased to have the opportunity to share these results with the cancer research community at AACR,” said Daniel J. O’Connor, President and Chief Executive Officer of Advaxis.

This year’s meeting will focus on “Delivering Cures through Cancer Science,” and will take place in New Orleans, Louisiana April 16-20 at the Ernest N. Morial Convention Center. Once confirmed, the time and date of the Advaxis poster presentation will be available on Advaxis.com.

HPV-Associated Head and Neck Cancers

More than 90 percent of head and neck squamous cell oropharyngeal cancers originate from the mucosal linings of the oral cavity, pharynx, or larynx. Currently, 60 to 80 percent of these cancers are caused by HPV. Head and neck cancers are treated by surgical removal of the cancer and lymph nodes, often followed by radiation and chemotherapy based on the extent of the disease. While patients may achieve good long-term survival, standard treatments can change their physical appearance and are associated with significant short and long-term toxicities which may interfere with salivary gland function, taste, smell, and the ability to swallow.

The incidence of HPV-associated head and neck cancers has been increasing at an epidemic rate, while head and neck cancers from other causes have been decreasing. According to the World Health Organization, approximately 15 to 20 percent of the 400,000 new cases of head and neck cancer are HPV-related. In the US, there are about 12,000 new cases of HPV-associated head and neck cancer per year and it affects men about 3 times more frequently than women. HPV-associated head and neck cancer is growing fastest in developed countries like the U.S.

About Axalimogene Filolisbac

Axalimogene filolisbac (ADXS-HPV) is Advaxis’ lead Lm Technology™ immunotherapy candidate for the treatment of HPV-associated cancers and is in clinical trials for three potential indications: invasive cervical cancer, head and neck cancer, and anal cancer. In a completed randomized Phase 2 study in recurrent/refractory cervical cancer, axalimogene filolisbac showed apparent prolonged survival, objective tumor responses, and a manageable safety profile alone or in combination with chemotherapy, supporting further development of the company’s Lm Technology™. Axalimogene filolisbac has Orphan Drug Designation in the U.S. for the treatment of anal cancer.

About Advaxis, Inc.

Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology™, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’ lead Lm Technology™ immunotherapy, axalimogene filolisbac, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three potential indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The U.S. Food and Drug Administration (FDA) has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development.

For additional information on Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.

Forward-Looking Statements

This media statement contains forward-looking statements, including, but not limited to: statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies; and the safety and efficacy of Advaxis’ proprietary immunotherapies. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2015, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

CONTACTS:

Company:
Advaxis, Inc.
Greg Mayes, Executive Vice President and COO
mayes@advaxis.com
609.250.7515

Media Contact:
JPA Health Communications
Catherine Brady
Catherine@jpa.com
617.945.9316

(OGES) Debuts Lithium-ion Motorcycle Batteries at 75th Annual Daytona Beach Bikefest

Oakridge Global Energy Solutions: A New Era In Battery Manufacturing

Palm Bay, FL, March 02, 2016  — Oakridge Global Energy Solutions, Inc.
Info@oakg.net

Oakridge Global Energy Solutions:
A New Era In Battery Manufacturing

Oakridge Commercial Introduction of Lithium-ion Motorcycle Batteries at 75^th Annual Daytona Beach Bikefest

FOR IMMEDIATE RELEASE

Oakridge Motorcycle Starter Batteries

March 2, 2016 Palm Bay, Florida – Oakridge Global Energy Solutions, Inc. (OTCQB: “OGES”) is excited to announce the commercial introduction of its groundbreaking Liberty Series lithium ion motorcycle batteries at the 75^th anniversary of the iconic Daytona Beach Bikefest.  The Daytona Beach Bikefest runs from March 4 through the 14^th and Oakridge will be promoting and selling its Liberty Series motorcycle batteries at the Company’s booth at Daytona Beach’s Rossmeyer Harley Davidson right off of highway I-95.

Oakridge’s Liberty Series provides a uniquely “Made-in-the-USA” lithium ion, long-life, high reliability battery solution for all models of the iconic “Made-in-the USA” Harley Davidson, Indian and Victory motorcycles.  These are larger bikes with larger engines that require a powerful battery in order to start.  Historically owners of motorcycles who did not ride at least every 7 to 14 days were forced to purchase a battery trickle charger, or tender, along with somewhat frequent purchases of replacement AGM or Lead Acid batteries, due to their propensity to go flat and not start their bikes.

In addition, the powerful Oakridge Liberty Series lithium ion batteries remove as much as 17 pounds from the weight of the largest bikes as the Oakridge high-tech lithium batteries are significantly lighter than their lead acid predecessors due to the inherent lightness of lithium, which is the lightest metal in existence with an atomic weight of only 3, whereas lead has an atomic weight more than 27 times heavier.

By utilizing the Oakridge specialized battery management system and proprietary electro-chemistry, the Liberty Series motorcycle batteries go without charging for up to 12 months and still start a large motorcycle, because Oakridge’s Liberty Series batteries have a typical self discharge of 1% or less per month while the traditional lead acid and AGM cells typically self discharge at 10% to 15% per month.  Moreover, the Liberty Series batteries have an average lifespan of 5 to 10 years depending on the application as opposed to lead acid and AGM batteries that have an average lifespan of only 18 to 36 months.  This provides the motorcycle enthusiast with a much better motorcycle ownership experience and allows them to focus on the having fun with their bike and not on the battery routinely being flat.

“Our senior management team at Oakridge owns more than 15 American motorbikes here in the US and we all agreed early on that one of our key products would be motorbike batteries because we were all fed up with the standard lead acid batteries always going flat,” said Oakridge Executive Chairman and CEO, Steve Barber. “With my travel schedule over the past 30+ years, I have been a frequent owner of flat batteries when I wanted to have a nice relaxing ride.  We have spent the past 12 months refining and finalizing this product and are excited to announce that we are delivering the Liberty Series product line to the public at the iconic Daytona Beach Bikefest.  And the fact that this year is the famous event’s 75^th anniversary makes it that much better for us to have the commercial release of the Liberty Series at this year’s Bikefest.  With the commercial production release of the “Made in USA” Liberty Series batteries, Oakridge is continuing our fundamental mission to onshore manufacturing back to the US and we will continue to introduce new and exciting products.  As avid motorbike enthusiasts, our team at Oakridge is very excited to be commercially shipping our Liberty Series batteries beginning this week. We are also excited to announce that we will also be gradually extending our Liberty Series batteries to all other brands of motorcycles, jet skis, snowmobiles and boats as well.”

The Oakridge product development team has worked with numerous lithium battery professionals internally and externally to produce the Liberty Series product range.  The batteries are all manufactured in the Oakridge Palm Bay, Florida facility.  Battery pack design, battery management system design, and mechanical design of all component systems have been completed by leaders in their respective industry segments in the USA.

“We are really excited about this product.  Oakridge is THE “Made In The USA” battery company and included in our initial product release for the Liberty Series are batteries for the three quintessential iconic American motorcycles: Harley Davidson, Indian, and Victory.  We conducted standing tests where we installed our battery in one of my personal bikes and let it sit for 32 days.  On the 32^nd day it started up better than it would with a brand new lead acid battery.  We also gave one of our early prototypes to a Harley Davidson owner over a year ago.  He was called to active duty with the military and was out of country for just over 1 year.  He called us up and told us that after 1 year of his bike in storage without starting and without a battery tender his bike started right up with our prototype Liberty Series battery!  This is just one more example of how Oakridge it taking the worry out of our favorite hobbies while at the same time providing a much safer, zero maintenance, long-life battery system with our high quality ‘Made in USA’ battery systems,” adds Mr. Barber.

http://www.globenewswire.com/NewsRoom/AttachmentNg/9866e068-cea9-4a5e-a1db-28e44fc73c7b
Oakridge Liberty Series Batteries

About Oakridge Global Energy Solutions, Inc.

Oakridge Global Energy Solutions Inc., is a publicly traded company, trading symbol: OGES on the OTCQB with a market capitalization of approximately USD $ 200,000,000, whose primary business is the development, manufacturing and marketing of energy storage products. Additional information can be accessed on the company’s website www.oakridgeglobalenergy.com

Forward-Looking Statements Disclaimer: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.

Contact:
Oakridge Global Energy Solutions, Inc.
www.oakridgeglobalenergy.com
3520 Dixie Highway
Palm Bay, 32905, Florida, USA
Ph: (321) 610-7959
Email: ir@oakg.net

Investor Inquiries:

Benchmark Advisory Partners LLC
Timothy Connor
Toll Free: (866) 703-4778
admin@bmarkadvisory.com

And:

Dutch DeWaard
Business Development
DreamTeamNetwork (DTN)
Austin, TX
www.DreamTeamNetwork.com
512.758.8877 Office
480.734.5834 Mobile
Dutch@DTN.fm

And:

Mike King
Princeton Research
www.princetonresearch.com
702.650.3000
mike@princetonresearch.com

(GWGH) to Present at the 28th Annual ROTH Conference

MINNEAPOLIS, March 01, 2016  — GWG Holdings, Inc. (NASDAQ:GWGH) (“GWG” or “the Company”), a specialty finance company and leader in the life insurance secondary market, announced today that the Company will be presenting at the upcoming 28^th Annual ROTH Conference at the Ritz Carlton in Laguna Niguel, CA.

Jon Sabes, Chief Executive Officer, Michael Freedman, President, and Bill Acheson, Chief Financial Officer, will be presenting at the conference on Tuesday, March 15 at 12:30pm Pacific Time. In addition to presenting, GWG will be attending one-on-one meetings with investors throughout the conference, which runs from March 13 through March 16. A live webcast of the presentation will be available at http://wsw.com/webcast/roth30/gwgh and a replay will be available in the investor relations section of the Company’s website at www.gwglife.com.

To receive additional information or to schedule a one-on-one meeting, please contact your ROTH Capital Partners sales representative or Larry Clark at lclark@finprofiles.com.

About GWG Holdings, Inc.

GWG Holdings, Inc. (NASDAQ:GWGH) is a specialty finance company and a leader in the secondary market for life insurance. GWG is dedicated to creating a vibrant secondary life insurance market for the economic benefit of seniors seeking post-retirement financial solutions, investors seeking yield derived from non-correlated assets, financial advisors seeking value-added products and services for their clients, and shareholders seeking to benefit from the growth of this marketplace. As of September 30, 2015, GWG’s growing portfolio consisted of $900 million in face value of benefits. Since 2006, GWG has purchased nearly $1.8 billion in life insurance policy benefits and paid seniors over $303 million for their policies.

Investor Contacts:
Larry Clark (310) 622-8223
Kristen Papke (310) 622-8225
Financial Profiles, Inc.
GWGH@finprofiles.com

Media Contacts:
Stefan Prelog
Senior Vice President
Rubenstein Public Relations, Inc.
(212) 843-8076
sprelog@rubenstein.com

Rose Reifsnyder
Senior Vice President, Marketing 
GWG Holdings, Inc.
(612) 840-7204
rreifsnyder@gwglife.com

(APIC) Crédit Mutuel Arkea Harnessing APIs Powered by Apigee

The Cooperative Banking and Insurance Company Using Apigee API Management Software to Help Improve Access to Its Online Services

SAN JOSE, Calif., March 01, 2016  — Apigee® (NASDAQ:APIC), developer of an intelligent API platform for digital business, today announced that Crédit Mutuel Arkea, a leading mutual, cooperative banking and insurance company in France, has selected the Apigee Edge API management software to help it harness the power of APIs (application programming interfaces) for its online banking and insurance solutions.

With APIs at the center of Crédit Mutuel Arkea’s online development strategy, the banking and insurance company selected Apigee software in order to unlock new efficiencies and help drive customer growth on Web and mobile platforms.

“We are seeing banking and insurance companies at the forefront of digital transformation.  Apigee’s intelligent API platform can help Crédit Mutuel Arkea use APIs in a coherent and sophisticated way to help securely share data and services across devices,” explained Denis Dorval, vice president, EMEA, Apigee.

To meet its increased need for responsiveness and flexibility, Crédit Mutuel Arkea plans to expose APIs for both partner applications and internal applications. Acceleration of customer acquisition by improving the user experience of its retail information system is a key priority. In response to this strategic challenge, the company is implementing a modular and flexible IT architecture, and it is leveraging APIs to help its transformation, deploying a “mobile first” approach, and developing marketing operations with major players.

“The acquisition of the Apigee Edge API management software will help Crédit Mutuel Arkéa to improve the online access of its new services for its clients and partners. This is in line with Arkéa’s strategy to grow its online banking market and digital financial services,” commented Marc Chéreau, Director of Computer Studies, Crédit Mutuel Arkéa.

Apigee’s intelligent API platform helps businesses use APIs to securely share data and services across devices to serve customers and use data to continually improve the customer experience. Apigee’s platform today includes Apigee Edge, its flagship API management software; Apigee Insights, an advanced predictive analytics product; and Apigee Link, an API-first product for the Internet of Things (IoT). Most recently, Apigee introduced Apigee Sense, an intelligent API security product.
                                                                                                                                   
About Crédit Mutuel Arkea
Crédit Mutuel Arkea is a retail banking and insurance cooperative mutual bank, not listed on the stock exchange. Crédit Mutuel Arkea is entirely owned by its customer-members. Crédit Mutuel Arkea is composed of three regional federations representing three main French geographic zones (Brittany in the West, the South West and Massif Central in the middle of France). Crédit Mutuel Arkea also has a presence across the country thanks to its corporate and online subsidiaries (Fortuneo, Monext, Financo, Federal Finance, Suravenir, CFCAL…). Crédit Mutuel Arkea employs nearly 9000 people, counts 3,700 administrators and has a total of 3.6 million members and customers. The bank has 110 billion Euros in total assets. Crédit Mutuel Arkea ranks among the leading banks with headquarters in region. For further information, go to www.arkea.com.

About Apigee
Apigee® (NASDAQ:APIC) provides an intelligent API platform for digital business. Many of the world’s largest organizations select Apigee to enable their digital business, including 30 percent of the Fortune 100, five of the top six Global 2000 retail companies, and five of the top 10 global telecommunications companies. Apigee customers include global enterprises such as Walgreens, Burberry, Morningstar, and First Data. Apigee is headquartered in San Jose, California and has over 400 employees worldwide.

Safe Harbor Statement
This press release contains forward-looking statements, including statements regarding market adoption of digital technologies, planned customer adoption and implementation of Apigee’s products, potential future customer opportunities and opportunities between Apigee and Arkea. These forward-looking statements are based on current expectations and are subject to inherent uncertainties, risks and changes in circumstances that are difficult or impossible to predict. Consequently, you should not rely on these forward-looking statements. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such uncertainties, risks and changes in circumstances, including without limitation risks and uncertainties related to market adoption of digital technologies, the ability of Apigee’s software to meet its customers’ needs, the quality of Apigee’s software, support and services and related infrastructure capacity and any incorrect implementation or use of Apigee software.

The foregoing list of factors is not exclusive. Additional risks and uncertainties that could affect Apigee’s financial and operating results are included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in Apigee’s Quarterly Report on Form 10-Q filed with the SEC on December 8, 2015. Apigee’s SEC filings are available on the Investor Relations section of the Company’s website at http://investors.apigee.com and on the SEC’s website at www.sec.gov. Apigee disclaims any obligation to update the forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Connect with Apigee

Apigee blog: https://blog.apigee.com/front
Apigee community: https://community.apigee.com/
Twitter: https://twitter.com/Apigee
LinkedIn: https://www.linkedin.com/company/apigee

Apigee is a registered trademark in the U.S. Other product or company names mentioned may be trademarks or trade names of their respective companies.

Apigee Media Contacts:

Apigee Europe Limited
Florence Giuly-Davis
PR Paradigm for Apigee
06 16 61 77 57
florence@prparadigm.com

US/Global:
press@apigee.com

Press contact Crédit Mutuel Arkéa:

Florence Eckenschwiller 
+33 2 98 00 01 91 
florence.eckenschwiller@arkea.com

(MTLS) Launches the Materialise Mimics Care Suite, the Platform for 3D Printing in Hospitals

Materialise NV (NASDAQ:MTLS), is proud to announce the launch of the Materialise Mimics Care Suite, a full suite of software and solutions for 3D printing within hospitals. The Materialise Mimics Care Suite is an open and flexible platform that includes planning and design software tools, 3D printed anatomical models and surgical guides, and patient-specific implants. Launched during AAOS, the American Association of Orthopaedic Surgeon’s Annual Meeting, the Suite also introduces Materialise Mimics inPrint, a new software solution that enables surgeons to create accurate medical models for 3D printing in hospitals without the need of advanced clinical engineering support.

With the Materialise Mimics Care Suite, Materialise brings together medical software and services, both established and new, into a single, neutral platform that facilitates the further integration of 3D planning and printing into hospitals. For example, Materialise Mimics inPrint allows clinicians to 3D print in hospitals by connecting data from all modern imaging systems to the ever expanding range of 3D printers on the market. The Materialise Mimics Care Suite also includes software for predictive planning and communication; patient-specific guides that transfer a co-created surgical plan to the OR; and patient-specific models and implants that enable surgeons to treat complex cases.

Materialise Founder and CEO, Wilfried Vancraen, states, “For more than 25 years, we at Materialise have been identifying meaningful applications of 3D printing and developing the backbone of software and solutions needed to successfully bring them to market. We see incredible potential for 3D printing in hospitals, but have also recognized that many existing solutions have slowed adoption of the technology. Therefore, we have developed the Materialise Mimics Care Suite with the aim of helping hospitals better integrate 3D printing and begin unleashing the benefits it offers, which include potential cost savings and patient care improvement.”

Since their foundation, Materialise has been providing leading-edge, 3D visualization and printing solutions to their extensive list of hospital, academic and medical device customers. Materialise’s open and flexible platform of software and services forms the foundation of certified medical 3D Printing, in clinical as well as research environments, enabling medical professionals to revolutionize patient treatment and make the world a better and healthier place.

About Materialise
Materialise incorporates more than 25 years of 3D printing experience into a range of software solutions and 3D printing services, which together form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines the largest group of software developers in the industry with one of the largest 3D printing facilities in the world. For additional information, please visit: www.materialise.com.

About Materialise’s Medical Division
Materialise Medical, which has pioneered many of the leading medical applications of 3D printing, enables researchers, engineers and clinicians to revolutionize innovative patient-specific treatment that helps improve and save lives. Materialise Medical’s open and flexible platform of software and services, Materialise Mimics, form the foundation of certified Medical 3D Printing, in clinical as well as research environments, offering virtual planning software tools, 3D-printed anatomical models, and patient-specific surgical guides and implants. For additional information, please visit: http://hospital.materialise.com/

Cautionary Statement on Forward-Looking Statements
Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements relating to, among other things, our planned commercialization efforts and regulatory approvals of our technologies as well as the success thereof and our research and development projects. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control that may cause our actual results to differ materially from our expectations. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

(NVIV) FDA Acceptance of Neuro-Spinal Scaffold™ Submission

InVivo Therapeutics Holdings Corp. (NVIV) today announced that the U.S. Food and Drug Administration (FDA) has accepted its proposed Humanitarian Device Exemption (HDE) modular shell submission and review process for the Neuro-Spinal Scaffold™. This investigational device is being studied in the INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury.

The modular HDE review process is based on a submission of individual sections or “modules” that constitute a complete HDE submission once all have been submitted. The modular approach allows the FDA to review each module separately, allowing the applicant to receive timely feedback and potentially resolve any deficiencies earlier in the review process compared to a traditional HDE application. InVivo’s HDE modular shell is comprised of three modules: a preclinical studies module, a manufacturing module, and a clinical data module. Following the submission of each module, the FDA reviews and provides feedback, typically within 90 days. Upon receipt of the final module, the FDA will make a filing decision that, if positive, triggers the HDE 75-day review clock for an approval decision.

“InVivo’s regulatory approach centers on efficiency and swiftness to market,” Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said. “We expect to submit and receive acceptance of the preclinical module by the end of this year and plan to submit the manufacturing and clinical modules in 2017.”

About the Neuro-Spinal Scaffold™ Implant

Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect,” “designed to,” “potentially,” and similar expressions, and include statements regarding the benefits of the modular shell submission and review process and the timing of FDA review and acceptance of HDE preclinical module and future modular submissions. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the company’s ability to commercialize its products; the company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2014, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

(OGES) Orlando PGA Merchandise Show Huge Success For Oakridge

Oakridge Global Energy Solutions: A New Era In Battery Manufacturing

Palm Bay, Florida, March 01, 2016  — Oakridge Global Energy Solutions, Inc.
Info@oakg.net

Oakridge Global Energy Solutions:
A New Era In Battery Manufacturing

Orlando PGA Merchandise Show Huge Success For Oakridge

FOR IMMEDIATE RELEASE

  http://www.globenewswire.com/NewsRoom/AttachmentNg/12f42474-7c2d-40f8-b6cd-573d9e234977
Fully electric golf car in Oakridge display

March 1, 2016 Melbourne, Florida – Oakridge Global Energy Solutions, Inc. (OTCQB: “OGES”) is excited to announce a major success at the Orlando PGA Merchandise Show, one of the biggest annual golf industry conventions in the world.

Directly at the show, Oakridge received more than $250,000 USD of immediate booked orders and follow on commitments of more than $20,575,000 USD.  The state-of-the-art, “Made in USA”, Oakridge Pro-Series Lithium Ion Golf Car battery systems are based on a proprietary design of electro-chemistry, safety, and electronics which results in cost effective, high performance lithium power now being available from a US manufacturer for the golfing industry.

By utilizing the Oakridge proprietary battery management system, golf car and local electric vehicle users of the revolutionary Pro-Series battery systems can now utilize their smart device such as phone, tablet, watch, or laptop, to monitor the capacity, range, speed, and health of their battery powered system.  This provides the user with the information power to go along with the battery power to more fully enjoy their round of golf or their local area electric vehicles.

Using fully electric golf cars and local area electric vehicles allows less dependence on foreign oil; provides a much more enjoyable and quiet round of golf; and has none of the noise and emissions associated with combustion engines.  By utilizing US made lithium batteries, Oakridge directly plays a role in reducing our imports and dependence on Chinese batteries and foreign oil, and instead of outsourcing jobs to offshore, Oakridge is leading the charge to on-shore jobs back to the US.  With Oakridge Pro-Series battery systems the user can enjoy a green system with low carbon foot print while helping to put America back to work, all at a competitive price.

“The Pro Series golf and local electric vehicle batteries continue to be an absolute game changer for the golf and local area EV markets,” said Oakridge Executive Chairman and CEO, Steve Barber. “We have spent the past 18 months refining and finalizing this product and are excited to announce that we are beginning production shipments in March.  We at Oakridge are continuing our mission to onshore manufacturing back to the US and will continue to introduce new and exciting products.  As avid golfers, our team at Oakridge is very excited to be shipping this product into the golfing market and the reception by our customers has been tremendous.”

The Oakridge development team has partnered up with researchers in the US, Germany, and Japan to develop this entire system of cell chemistry, battery management electronics, and overall battery system.

“We are all about game-changing technology and products at Oakridge.  Oakridge is THE ‘Made In The USA’ battery company that has the talent and technology to develop and produce these types of products for our customers in designing state-of-the-art high performance customer oriented battery systems.   With our Pro Series battery systems, we have now greatly expanded the effective daily range of the golf car and small local electric vehicle, making them a practical reality for immediate application to all aspects of the golfing industry and golfing communities, while at the same time providing a much safer, low maintenance, zero emissions vehicle by virtue of the more robust chemistry and the battery management systems we have designed for this product,” adds Mr. Barber.

http://www.globenewswire.com/NewsRoom/AttachmentNg/369072d4-e855-4b15-a18a-bbe8c52fbe94

Oakridge Battery Management System User Interface
[enlargement]

About Oakridge Global Energy Solutions, Inc.

Oakridge Global Energy Solutions Inc., is a publicly traded company, trading symbol: OGES on the OTCQB with a market capitalization of approximately USD $ 200,000,000, whose primary business is the development, manufacturing and marketing of energy storage products. Additional information can be accessed on the company’s website www.oakridgeglobalenergy.com

Forward-Looking Statements Disclaimer: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.

Contact:
Oakridge Global Energy Solutions, Inc.
www.oakridgeglobalenergy.com
3520 Dixie Highway
Palm Bay, 32905, Florida, USA
Ph: (321) 610-7959
Email: ir@oakg.net

Investor Inquiries:

Benchmark Advisory Partners LLC
Timothy Connor
Toll Free: (866) 703-4778
admin@bmarkadvisory.com

And:

Dutch DeWaard
Business Development
DreamTeamNetwork (DTN)
Austin, TX
www.DreamTeamNetwork.com
512.758.8877 Office
480.734.5834 Mobile
Dutch@DTN.fm

And:

Mike King
Princeton Research
www.princetonresearch.com
702.650.3000
mike@princetonresearch.com

(OPCO) Unveils New Innovative Products at Global Pet Expo 2016

Products Designed to Enhance the Bond Between Pet and Pet Parent

(ELMD) Names John Kowalczyk Vice President of Sales

Electromed, Inc. (NYSE MKT: ELMD), maker of the SmartVest^® Airway Clearance System, today announced that John Kowalczyk has joined the Company as Vice President of Sales and will oversee all domestic sales initiatives. Along with medical sales leadership, growing product lines, and the success of building new businesses, Kowalczyk brings to Electromed an outlook of promoting a culture of learning, improvement, and executing best practices.

“John has a proven track record of leading and developing high performing sales teams that deliver sustainable growth and profit. In addition, he has consistently created winning and positive cultures that reward achievement, engender loyalty, and celebrate success,” said Kathleen Skarvan, President and Chief Executive Officer.

Kowalczyk previously served as Vice President of Sales at Medtronic, Inc. in the areas of pain stimulation and target drug delivery, neuromodulation, gastroenterology, and urology. Most recently, he served as President of DorsaVi, an Australia-based company commercializing products for the elite sports, occupational health and safety, and medical physiotherapy markets. Kowalczyk holds a Bachelor of Arts Degree in International Relations from the University of Wisconsin, Madison. He will report to Skarvan.

About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest^® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota and founded in 1992. Further information about the Company can be found at www.smartvest.com.

(AST) Appoints Stephen L. Cartt President and Chief Executive Officer

Don M. Bailey Appointed to Board of Directors and Named Chairman

FREMONT, Calif., Feb. 29, 2016  — Asterias Biotherapeutics, Inc. (NYSE MKT: AST) today announced the appointment of pharmaceutical industry veteran Stephen L. Cartt as President and Chief Executive Officer and member of the Board of Directors. In addition, the Company announced the appointment of Don M. Bailey to its Board of Directors. Mr. Bailey, who previously served as President and Chief Executive Officer of Questcor Pharmaceuticals Inc. until its sale for $5.6 billion in 2014 to Mallinckrodt, plc, was named Chairman of the Board of Directors of Asterias. Both appointments are effectively immediately. Mr. Cartt replaces Pedro Lichtinger, who served as President, CEO and a member of the Board of Directors since June 2014. Mr. Bailey succeeds Alfred D. Kingsley as Chairman. Mr. Kingsley will remain on the Asterias Board of Directors.

“Steve Cartt and Don Bailey have superb track records of creating substantial shareholder value over time by building successful, high growth pharmaceutical businesses, advancing products through the development process, and commercializing therapies that address conditions with high unmet therapeutic needs. In addition, Steve and Don have an extraordinary history of success working together to build significant shareholder value,” said Mr. Kingsley. “Our Board is excited that both Steve and Don are joining Asterias in its efforts to realize the full potential of its AST-VAC1, AST-VAC2, and AST-OPC1 clinical programs. The Board also wishes to thank Pedro Lichtinger for his leadership through a crucial phase of the Company’s development.”

“During the past year and a half as a member of the BioTime Board, I’ve had the opportunity to learn about the exciting potential of the Asterias AST-VAC1, AST-VAC2, and AST-OPC1 clinical-stage programs,” said Mr. Cartt. “I look forward to working with the Asterias team, Don and the Board to further the company’s clinical development of these important treatments. We believe that over time, these efforts have the potential to build significant returns for our shareholders.”

Mr. Cartt began his career in the pharmaceutical industry with ALZA Corporation where he held a variety of R&D and commercial positions. He moved to Elan Pharmaceuticals and served as Senior Director of Strategic Marketing before joining Questcor in 2005. At Questcor, he served as Executive Vice President and Chief Business Officer prior to being appointed Chief Operating Officer in 2012. Questcor experienced high growth in revenues and earnings during this period, while its market valuation increased more than 200 fold from less than $25 million in 2007 to $5.6 billion at the time of its sale in 2014. After the acquisition of Questcor in August 2014, Mr. Cartt served in a transitional role as Chief Operating Officer of Mallinckrodt’s AutoImmune and Rare Diseases Business Unit until October 2014. Mr. Cartt has been a member of the BioTime, Inc. Board of Directors since November 2014, a position from which he has resigned in conjunction with accepting the CEO position at Asterias, a publicly traded subsidiary of BioTime (NYSE MKT: BTX). He holds a B.S. in biochemistry from the University of California, Davis and an MBA from Santa Clara University.

Mr. Bailey brings to Asterias substantial management, board, and corporate governance experience. From 2006 through 2014, Mr. Bailey served on the Board of Directors of Questcor, was its President and CEO from 2007 through 2014, and at various times, chaired or was a member of several board committees including Questcor’s Strategic Initiatives Committee. Since the sale of Questcor, Mr. Bailey has served on the Board of Directors and as Chairman of the Portfolio Committee of Mallinckrodt. He is also a director, audit committee chair, and a member of the Transaction Committee of Biotie Therapies Corp., a public pharmaceutical company headquartered in Turku, Finland. Biotie went public in the U.S. through an IPO in June 2015 and entered into a Combination Agreement with Acorda Therapeutics in January 2016. Previously, Mr. Bailey served as the non-executive chairman and chairman of the Nominating and Corporate Governance Committee of STAAR Surgical Company, an ophthalmic products company, from 2005 through June 2014. In addition to his public company experience, he serves on the board of the Argyos School of Business at Chapman University in Orange, Calif. and is a Founding Board member of the University of California Irvine’s Institute for Applied Innovation. Mr. Bailey is also a Senior Fellow in Entrepreneurship at Pepperdine University.

Asterias will report results for its fourth quarter and full year 2015 in March. Further information on the release and the conference call will be provided as timing is finalized.

About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc. is a leading biotechnology company in the emerging field of regenerative medicine. The company’s proprietary, industry leading platforms are based on its pluripotent stem cell and dendritic cell immunotherapy technologies. Asterias is focused on developing therapies to treat conditions in several medical areas where there is high unmet medical need and inadequate available therapies. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury. AST-VAC1 (antigen-presenting autologous dendritic cells) has demonstrated promise in a Phase 2 study in acute myelogenous leukemia. AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic approach to dendritic cell vaccines. Additional information about Asterias can be found at www.asteriasbiotherapeutics.com.

Forward Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and “potential”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias’s filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements.

(ALDX) Reports Positive Results From Phase IIa Clinical Trial

NS2 Demonstrates Statistically Significant and Sustained Clinical Effects

Data Suggest Aldehyde Trapping as Novel Approach for the Treatment of Inflammatory Diseases

Conference Call to Be Held Today at 8:00 am ET 

LEXINGTON, Mass., Feb. 29, 2016  — Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today reported that the results of a randomized, parallel-group, single-center, double-masked, vehicle-controlled Phase IIa clinical trial of topical ocular NS2 in subjects with induced allergic conjunctivitis demonstrated statistically significant activity of NS2 over vehicle in reducing ocular itching and tearing.

Aldehydes are thought to be related to inflammatory conditions including allergic conjunctivitis, as well as other forms of ocular and non-ocular inflammation. NS2, a small molecule aldehyde trap, was tested in a conjunctival allergen provocation test (CAPT) model of allergic conjunctivitis.  One hundred healthy men and women with at least a two-year history of allergic conjunctivitis to grass, tree or ragweed pollen were enrolled and randomized in equal groups for treatment with topical ocular NS2 or vehicle.  The clinical endpoints in the trial included patient assessment (on a 0 to 4 point scale) of ocular itching and tearing, two prominent inflammation-related symptoms of allergic conjunctivitis.

Statistically significant differences were demonstrated for ocular itching (p<0.05) and ocular tearing (p<0.05) between NS2 and vehicle after single dose and multiple dose administration.  NS2 demonstrated durable effects throughout the three hours following CAPT challenge.  The effects of NS2 persisted across substantially all time points for all CAPT challenges despite a stronger than expected vehicle effect.  The reductions from baseline scores were of the same magnitude seen in the CAPT model with existing therapies utilized in the treatment of allergic conjunctivitis, and peak changes exceeded one point for both ocular itching and ocular tearing scores.

NS2 was generally well tolerated and there were no safety concerns during the trial. Transient and generally mild stinging was noted in the treatment arm.  Two patients dropped out of the trial during treatment.

Commenting on the results, Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, said, “To our knowledge, the data from this clinical trial represent the first example of clinical efficacy of an aldehyde trap in human disease. We are thrilled with the outcome of this trial and believe that the results suggest important insight into the physiology of inflammation and further applicability of aldehyde trapping in the treatment of inflammatory disease.”

Aldeyra is also performing a Phase II clinical trial of topical ocular NS2 in patients with noninfectious anterior uveitis, and a Phase II trial of dermatologic NS2 in patients with Sjögren-Larsson Syndrome.  The last visit for the last patient in the noninfectious anterior uveitis Phase II clinical trial occurred this month, and data from the trial are expected in the second quarter of 2016.

Conference Call

Aldeyra will hold a conference call on February 29, 2016 at 8:00 a.m. ET. Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer; David J. Clark, M.D., Chief Medical Officer; and Stephen Tulipano, Chief Financial Officer, will host a conference call to discuss results of the clinical trial. The dial-in numbers are 1-877-407-0784 for domestic callers and 1-201-689-8560 for international callers.  The conference ID number for both is 13631657.  A live webcast of the conference call will also be available on the investor relations page of Aldeyra’s corporate website at www.aldeyra.com.

After the live webcast, the event will remain archived on Aldeyra’s website for 60 days.  In addition, a telephonic replay of the call will be available until March 7, 2016. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers.  Please use event passcode 13631657.

About NS2

NS2 is an aldehyde-binding small molecule based on an innovative platform technology focused on trapping aldehydes, which are toxic and pro-inflammatory mediators of numerous diseases. By decreasing aldehyde load, NS2 may mitigate excessive inflammation and address diseases where aldehyde metabolism is impaired, including certain inborn errors of metabolism.

About Allergic Conjunctivitis

Allergic conjunctivitis is a common allergic disease that is thought to be mediated in part by pro-inflammatory aldehydes, and is characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in excessive tear production in addition to ocular itching, swelling, and redness.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap aldehydes. Aldeyra has completed Phase IIa testing of NS2 in subjects with induced allergic conjunctivitis, and has initiated clinical testing of NS2 for the treatment of Sjögren-Larsson Syndrome and noninfectious anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s plans for its product candidates and the development of NS2 and timing of the results from Aldeyra’s noninfectious anterior uveitis Phase II clinical trial. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “target,” “design,” “estimate,” “predict,” “potential,” “aim,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Aldeyra’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyra’s clinical trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; the ability to obtain and maintain regulatory approval to conduct clinical trials and to commercialize Aldeyra’s product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Aldeyra’s product candidates; the size and growth of the potential markets for Aldeyra’s product candidates and the ability to serve those markets; Aldeyra’s expectations regarding Aldeyra’s expenses and revenue, the sufficiency of Aldeyra’s cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyra’s product candidates; Aldeyra’s expectations regarding competition; Aldeyra’s anticipated growth strategies; Aldeyra’s ability to attract or retain key personnel; Aldeyra’s ability to establish and maintain development partnerships; Aldeyra’s expectations regarding federal, state and foreign regulatory requirements; regulatory developments in the United States and foreign countries; Aldeyra’s ability to obtain and maintain intellectual property protection for its product candidates; the anticipated trends and challenges in Aldeyra’s business and the market in which it operates; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Aldeyra’s Annual Report on Form 10-K for the year ended December 31, 2014 and Aldeyra’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov.  Additional factors may be described in those sections of Aldeyra’s Annual Report on Form 10-K for the year ended December 31, 2015, to be filed with the SEC in the first quarter of 2016.  In addition to the risks described above and in Aldeyra’s other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra’s results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 Ext. 205
stulipano@aldeyra.com

Investor Contact: 
David Burke
The Ruth Group
Tel: +1 646-536-7009
dburke@theruthgroup.com

(GLBL) Declares Fourth Quarter Dividend

BETHESDA, Md., Feb. 29, 2016  — TerraForm Global, Inc. (Nasdaq:GLBL), a global owner and operator of clean energy power plants, today announced that its Board of Directors declared its 4Q 2015 dividend on the Company’s Class A common stock of $0.275 per share. This represents a dividend of $1.10 per share on an annualized basis. The dividend is payable on March 17, 2016 to shareholders of record as of March 10, 2016.

As a first-time filer, TerraForm Global’s annual Form 10-K report is required to be filed by March 30, 2016, and the Company expects to release its 4Q results closer to that date.

“We now have a geographically diverse fleet of high-quality wind and solar assets comprising 814 MW spread across 6 countries,” said Brian Wuebbels, Chief Executive Officer.  “This reflects the addition of 36 MW from two solar power plants in Thailand that were originally contributed by SunEdison at the IPO when they were still under construction. These two power plants, named NPS Star and WXA, have now reached commercial operation and were transferred into our fleet in the first quarter. Our fleet remains fully contracted with creditworthy power off-takers, including state utilities and government agencies, with an average remaining contract life of approximately 18 years.”

About TerraForm Global

TerraForm Global is a renewable energy leader that is changing how energy is generated, distributed and owned. TerraForm Global creates value for its investors by owning and operating clean energy power plants in high-growth emerging markets. For more information about TerraForm Global, please visit: www.terraform.com.

Safe Harbor Disclosure

This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. These statements involve estimates, expectations, projections, goals, assumptions, known and unknown risks, and uncertainties and typically include words or variations of words such as “expect,” “anticipate,” “believe,” “intend,” “plan,” “seek,” “estimate,” “predict,” “project,” “goal,” “guidance,” “outlook,” “objective,” “forecast,” “target,” “potential,” “continue,” “would,” “will,” “should,” “could,” or “may” or other comparable terms and phrases. All statements that address operating performance, events, or developments that TerraForm Global expects or anticipates will occur in the future are forward-looking statements. They may include estimates of expected adjusted EBITDA, cash available for distribution (CAFD), earnings, revenues, capital expenditures, liquidity, capital structure, future growth, financing arrangements and other financial performance items (including future dividends per share), descriptions of management’s plans or objectives for future operations, products, or services, or descriptions of assumptions underlying any of the above. Forward-looking statements provide TerraForm Global’s current expectations or predictions of future conditions, events, or results and speak only as of the date they are made.  Although TerraForm Global believes its expectations and assumptions are reasonable, it can give no assurance that these expectations and assumptions will prove to have been correct and actual results may vary materially.

By their nature, forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. Factors that might cause such differences include, but are not limited to, our ability to integrate the projects we acquire from third parties or otherwise realize the anticipated benefits from such acquisitions; actions of third parties, including but not limited to the failure of SunEdison or other counterparties to fulfill their obligations; price fluctuations, termination provisions and buyout provisions in offtake agreements; delays or unexpected costs during the completion of projects under construction; our ability to successfully identify, evaluate and consummate acquisitions from SunEdison or third parties or changes in expected terms and timing of any acquisitions; regulatory requirements and incentives for production of renewable power; operating and financial restrictions under agreements governing indebtedness; the condition of capital markets and our ability to borrow additional funds and access capital markets; our ability to compete against traditional and renewable energy companies; hazards customary to the power production industry and power generation operations, such as unusual weather conditions, outages, and curtailment; and economic, social and political risks and uncertainties inherent in international operations, including our operations in emerging markets, the impact of foreign exchange rate fluctuations, the imposition of currency controls and restrictions on repatriation of earnings and cash, protectionist and other adverse public policies, including local content requirements, import/export tariffs, increased regulations or capital investment requirements; international business practices that may conflict with other customs or legal requirements to which we are subject, inability to obtain, maintain or enforce intellectual property rights, and being subject to the jurisdiction of courts other than those of the United States, including uncertainty of judicial processes and difficulty enforcing contractual agreements or judgments in foreign legal systems or incurring additional costs to do so. Furthermore, any dividends are subject to available capital, market conditions, and compliance with associated laws and regulations. Many of these factors are beyond TerraForm Global’s control.

TerraForm Global disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions, factors, or expectations, new information, data, or methods, future events, or other changes, except as required by law. The foregoing list of factors that might cause results to differ materially from those contemplated in the forward-looking statements should be considered in connection with information regarding risks and uncertainties, which are described in TerraForm Global’s Registration Statement Form S-1 filed the Securities and Exchange Commission (the “SEC”) on July 31, 2015, as well as additional factors it may describe from time to time in other filings with the Securities and Exchange Commission. You should understand that it is not possible to predict or identify all such factors and, consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

Contacts:

Media:
Anne Granfield
Finsbury for TerraForm Global
anne.granfield@finsbury.com 
+1 (646) 805-2033

Investors/Analysts:
Brett Prior
bprior@terraform.com 
+1 (650) 889-8628

(OPCO) Reports Record 2015 Fourth Quarter and Full-Year Results

(AVID) Customers Bring Home BRIT Awards

Winners and Nominees Embraced Avid Everywhere to Create Award-Winning Songs and Albums at the U.K.’s Most Prestigious Music Awards Ceremony

BURLINGTON, Mass., Feb. 26, 2016  — Avid^® (Nasdaq:AVID) today congratulated its many customers recognized for their craft as winners and nominees at this year’s BRIT Awards, held at The O2 Arena in London on Wednesday, February 24. An overwhelming number of the world’s most respected artists embraced Avid Everywhere^TM, using Avid Artist Suite creative solutions, including the industry-standard digital audio software Avid Pro Tools^®, to craft internationally acclaimed songs and albums.

Adele took home the British Album of the Year award for 25. Fellow nominees who also relied on Pro Tools include Coldplay for A Head Full of Dreams and Florence + the Machine for How Big, How Blue, How Beautiful.

British producer and Pro Tools user Charlie Andrew was presented with the first 2016 BRIT Award for British Producer of the Year earlier this month at the annual Music Producers Guild (MPG) Awards ceremony in London. Andrew collected this year’s Best Producer Award for his work with Alt-J, Marika Hackman and Sivu. Pro Tools user and rock producer Tom Dalgety was also acknowledged with a nomination in the category.

Other BRIT Award-winning projects by artists, producers and engineers who use Avid solutions in their studios include, Coldplay (British Group), Bjork (International Female Solo Artist) and Tame Impala (International Group). Adele also took home three more awards, British Single for huge number one single Hello, Female Solo Artist and the converted Global Success Award.

“Once again, we’re honored that the world’s most talented music professionals continue to choose Avid’s industry-leading audio solutions to record and produce the best music in Britain and across the world,” said Avid Chairman, President and Chief Executive Officer, Louis Hernandez, Jr. “We congratulate our BRIT Award-winning and nominated customers who inspire us with their outstanding artistic and technical achievements.”

About Avid
Through Avid Everywhere™, Avid delivers the industry’s most open, innovative and comprehensive media platform connecting content creation with collaboration, asset protection, distribution and consumption. Media organizations and creative professionals use Avid solutions to create the most listened to, most watched and most loved media in the world—from the most prestigious and award-winning feature films, to the most popular television shows, news programs and televised sporting events, as well as a majority of today’s most celebrated music recordings and live concerts. Industry leading solutions include Pro Tools®, Media Composer®, ISIS®, Interplay®, ProSet and RealSet, Maestro, PlayMaker, and Sibelius®. For more information about Avid solutions and services, visit www.avid.com, connect with Avid on Facebook, Instagram, Twitter, YouTube, LinkedIn, or subscribe to Avid Blogs.

© 2016 Avid Technology, Inc. All rights reserved. Avid, the Avid logo, Avid Everywhere, iNEWS, Interplay, ISIS, AirSpeed, Media Composer, Pro Tools, and Sibelius are trademarks or registered trademarks of Avid Technology, Inc. or its subsidiaries in the United States and/or other countries. The Interplay name is used with the permission of the Interplay Entertainment Corp. which bears no responsibility for Avid products. All other trademarks are the property of their respective owners. Product features, specifications, system requirements and availability are subject to change without notice.

PR Contacts:
Sara Griggs
Avid
sara.griggs@avid.com
310-907-6909

(GRPN) Expands Its Enterprise Data Center Portfolio

Local Commerce Leader Leverages Advanced In-House Computing Systems and Wholesale Data Center Solutions From RagingWire to Drive Its Global Business

(VASC) and Howard Root Found Not Guilty on All Charges in Short Kit Litigation

• Jury finds Vascular Solutions and Howard Root not guilty on all charges in criminal prosecution concerning alleged “off-label” promotion of Vari-Lase® Short Kit
• Jury’s verdict concludes litigation and is not subject to appeal
• Vascular Solutions demands Department of Justice retract its prior false and misleading public statements 

MINNEAPOLIS, Feb. 26, 2016  — Vascular Solutions, Inc. (Nasdaq:VASC) today reported that the jury in its federal trial in the Western District of Texas in San Antonio has returned a unanimous verdict of not guilty on all charges against the company and its CEO Howard Root regarding the alleged “off-label” promotion of the Vari-Lase Short Kit. Senior U.S. District Judge Royce Lamberth has entered an order dismissing the case that is final and is not subject to appeal.

Howard Root made the following comments:

“The company and I are vindicated by today’s verdict, but outraged by the obscene legal process we were forced to endure.” 

“We are appalled by the malicious behavior and lack of substantive oversight of the government officials who pursued this matter – in particular Assistant U.S. Attorneys Bud Paulissen and Christina Playton of the Western District of Texas, Consumer Protection Branch Trial Attorneys Timothy Finley and Charles Biro, and FDA Special Agent George Scavdis. There simply is no excuse for abusive and dishonest conduct in any U.S. governmental agency, much less in the Department of Justice and our law enforcement agencies.”

“We greatly appreciate the jury’s complete rejection of the government’s false allegations. But to get to this result, we were subjected to five years of attacks which forced us to hire 10 separate law firms at a cost of over $25 million to defend against a criminal prosecution that clearly was never warranted by the facts. This case centered on just one version of just one of our more than 100 medical devices – a version that was FDA-cleared, made up only 0.1% of our sales, and, by the government’s own admission, never harmed a single patient. To say that this prosecution was wrong-headed and disproportionate would be the understatement of the year.”

“While this matter is now over for Vascular Solutions and me, an upcoming criminal trial remains scheduled for one of the company’s sales representatives on obstruction of justice charges because he refused to change his grand jury testimony to match what these prosecutors wanted to hear.  It should now be obvious that our sales rep’s indictment was merely a malicious retribution by misguided prosecutors, an action that needs to be corrected immediately.  And after his indictment is dismissed, if the U.S. Attorney in San Antonio still wants to prosecute someone for obstruction of justice in this case, in my opinion he wouldn’t even have to leave his own office to find the most suitable person to indict.”

“Vascular Solutions is fortunate to have had the financial strength and dedicated employees necessary not only to fight, but to win. Most other companies would have been destroyed before they even set foot in the courtroom. In order to ensure that what happened to Vascular Solutions doesn’t happen to a defenseless company or individual, changes need to be made in the personnel and culture at the Department of Justice.”

“Every investigation that is being conducted by the prosecutors who were assigned to our case needs to be independently reviewed by the Department of Justice to make sure that their abusive and dishonest tactics are not being used on others. Furthermore, every current investigation of a medical device company concerning “off-label” promotion needs to be reviewed by the Department of Justice to make sure their prosecutors’ theories comply with the law, not just their wishes.”

“Looking forward, starting tomorrow Vascular Solutions will return our full focus and resources to developing medical devices to improve patient lives and create American jobs – vital pursuits that were clouded while we were defending ourselves against a malicious prosecution. Fortunately, throughout this process our employees have continued to carry on with business as usual. That commitment and our successful business model has positioned Vascular Solutions very well for continued success, especially now that this senseless distraction is behind us.”  

In order to correct the multiple false and misleading public allegations made by the Department of Justice concerning this matter, Vascular Solutions demands a prompt and complete corrective press release.

In particular, on November 13, 2014 the Department of Justice, Office of Public Affairs issued a press release that quoted Joyce Branda, the Acting Assistant Attorney General for the Civil Division, alleging that this matter was “a deceptive sales campaign led by the CEO of a public company.” The press release further quoted Ms. Branda alleging that the “sales campaign persisted in the face of FDA warnings, a whistleblower’s complaint to the CEO and a failed clinical trial showing that the device was less safe and less effective than a product that had already been approved.” As demonstrated by the evidence presented under oath at trial, all of these allegations were false.

Similarly, in a press release issued on July 28, 2014 by the Department of Justice, Office of Public affairs, Assistant Attorney General Stuart F. Delery was quoted characterizing Vascular Solutions as a company that “put profits over patient safety.” In the same press release, U.S. Attorney Robert Pitman was quoted describing Vascular Solutions as a company that “knowingly promote[d] medical devices for unapproved uses, causing federal health care programs to pay for services that cannot be reimbursed.” Again, the evidence presented under oath at trial demonstrated that all of these allegations were false.

Furthermore, at a medical devices conference held on October 15, 2015, Julie Taitsman, MD, JD, the Chief Medical Officer at Health and Human Services, Officer of Inspector General, publicly stated that Vascular Solutions had persisted in off-label marketing even when a clinical trial failed, and that Vascular Solutions had data showing that the Short Kit was less safe than a competitor’s. She further stated that this case was “hand-picked” by the government because it was such a strong case, and that the government “went on the offensive” in prosecuting Vascular Solutions. Not only did the evidence presented under oath at trial demonstrate that Dr. Taitsman’s allegations were false when made, but her characterization of the prosecution strategy documented its malicious nature and violated judicial rules against the making of extrajudicial public statements during the pendency of a case.

Mr. Root concluded with the following statement:

“Gratuitous public allegations are easy for the Department of Justice to make when a lawsuit starts and the accused is unable to respond. But now that the trial is over and the jury has rejected all of the government’s accusations, the Department of Justice needs to set the record straight in the interests of justice.  And after that, the Department of Justice needs to investigate what went wrong in our case and make internal changes in order to ensure that its next ‘hand-picked’ and ‘offensive’ criminal prosecution isn’t based on false allegations made by a money-motivated disgruntled former employee, which is what happened here.”

Background

The Vari-Lase Short Kit was sold by Vascular Solutions in the U.S. from October 2007 through July 2014 under an FDA 510(k) clearance for the treatment of varicose veins and varicosities associated with superficial reflux of the great saphenous vein and for treatment of incompetence and reflux of superficial veins in the lower extremity. Sales of the Short Kit during the seven years it was on the U.S. market totaled $534,000, representing just 0.1% of Vascular Solutions’ U.S. sales of all products during those years.  Over two-thirds of Vascular Solutions’ sales representatives never sold even a single unit of the Short Kit, and the Short Kit was never the subject of any reported serious adverse event in any patient.

The allegations advanced by the prosecutors at trial concerned whether Vascular Solutions and Howard Root engaged in a promotional campaign to encourage members of Vascular Solutions’ sales force to speak to physicians about the use of the Short Kit to treat varicose perforator veins in the leg and whether that use was outside the Short Kit’s FDA-cleared labeled indications for use and therefore an “off-label” use.  The jury unanimously rejected all of the prosecutors’ allegations.

About Vascular Solutions

Since its founding by Howard Root in 1997, Vascular Solutions has developed over 100 new medical devices that are used by physicians to treat a wide variety of vascular diseases, from heart attacks to peripheral arterial disease. The company’s most recent major product in development is RePlas™ freeze-dried plasma, which is being developed in collaboration with the U.S. Army for use on the battlefield to save the lives of soldiers suffering blood loss, due to a bullet wound or roadside bomb. The Vari-Lase Short Kit matter is the only allegation of a legal compliance issue that the company has received in its 20-year history.

For further information on Vascular Solutions, connect to www.vasc.com.

Investors:

Phil Nalbone
VP of Vascular Solutions
PNalbone@vasc.com (763) 656-4371

Media:

Jon Austin
J Austin & Associates
jon@jaustingroup.com (612) 839-5172

(CTSO) Data Presented on First CytoSorb® Investigator-Initiated Septic Shock Study

Encouraging top line results fuel hopes for potentially life-saving treatment

MONMOUTH JUNCTION, N.J., Feb. 26, 2016  — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, summarized data from the first CytoSorb® investigator-initiated septic shock study presented yesterday at the  26th Symposium for Intensive Medicine + Intensive Care in Bremen, Germany.

Dr. Sigrun Friesecke, Senior Intensivist of the medical intensive care unit (MICU) at Greifswald University in Germany, presented top line data from a prospective, single arm study in 22 patients with refractory late-stage septic shock and multiple organ failure at her institution.  All patients had refractory septic shock despite high doses of vasopressors, respiratory failure requiring artificial ventilation or extracorporeal membrane oxygenation (ECMO), anuric (no urine production) kidney failure requiring dialysis, and a significantly elevated initial mean lactate level of 8 mmol/L, indicating extreme metabolic and physiologic derangement.  In these patients, all intensive care therapeutic options had been exhausted.  Patients underwent consecutive twelve-hour extracorporeal  CytoSorb® treatments over several days, using a new CytoSorb® cartridge for each treatment.

As reported recently by Conrad (2015), a similar patient population (n=16) receiving standard of care treatment with persistent refractory septic shock that could not be reversed, with respiratory failure on mechanical ventilation, initial lactate levels of 6.1 ± 4 mmol/L, and 75% requiring renal replacement therapy had a mortality of 100% at 28 days¹.

Preliminary key findings of the CytoSorb® Greifswald study:

• 28-day-survival was 41%, an approximately 30-40% absolute improvement in survival compared to what was expected (0-10%)
• Resolution of shock, the main cause for mortality in this patient population, was achieved in 68% of the patients with CytoSorb® therapy, which translated into improvement in clinical outcomes
• Reduction of IL-6, one of the cytokines most closely associated with severity of illness, inflammation, and mortality in sepsis, decreased rapidly from initial mean values of approximately 87,000 pg/mL, to below 10,000 pg/mL after 24 hours of treatment

Data analysis continues and more details of this study are expected to submitted for publication in the near future.

Dr. Axel Nierhaus, senior consultant at the Department for Intensive Care Medicine at University of Hamburg – Eppendorf, Germany, who chaired the symposium session, summarized the study as a “significant step to establish CytoSorb as a regular therapy for those moribund patients”.

Sepsis is the result of an overzealous immune response to a serious infection often driven by an excessive production of cytokines, or “cytokine storm”, and other inflammatory mediators and toxins.  It is one of the leading causes of death and disability worldwide, striking an estimated 27 million people annually and killing a third of them, despite the use of antibiotics and the best medical care.  Septic shock is the most deadly form of the disease, where patients develop persistent, life-threatening low blood pressure that compromises blood and oxygen delivery to vital organs in the body.  Common to all septic shock patients is the need for vasopressors – potent drugs such as norepinephrine, dobutamine, and vasopressin – that attempt to artificially increase blood pressure by increasing cardiac output or shunting blood from non-vital organs and the arms and legs, to the core vital organs.  Patients who require maximal doses of multiple vasopressors represent the most challenging patients with the highest risk of death.  Refractory septic shock, despite the use of vasopressors, often results in irreversible organ injury due to ischemia and other factors.  The expected mortality of patients with prolonged refractory septic shock, particularly when combined with the failure of other organs, approaches 90-100%.  CytoSorb® is designed to reduce the inflammatory toxins that drive uncontrolled, deadly inflammation and refractory shock, and has been used to help stabilize blood pressure and regain control of many patients, particularly when used early and aggressively.

¹ Conrad, M., et. al., “Early prediction of norepinephrine dependency and refractory septic shock with a multimodal approach of vascular failure”, J Crit Care, 2015; 30:739-743.

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorb® is approved in the European Union with distribution in 32 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis, as well as in cancer immunotherapy.  These are conditions where the risk of death is extremely high, yet no effective treatments exist.  CytoSorb^® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure.  CytoSorb® has been used safely in more than 9,000 human treatments to date.

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.  The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others.  Additional information is available for download on the Company’s websites:  http://www.cytosorbents.com and http://www.cytosorb.com

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2015, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow Us on Facebook and Twitter